Stock code: 688363 Stock abbreviation: Bloomage Biotech Announcement No.: 2025-005

Bloomage Biotechnology Co., Ltd

Announcement on the adjustment and appointment of senior management

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

On March 18, 2025, Bloomage Biotechnology Co., Ltd. (hereinafter referred to as the "Company") held its first meeting

At the 16th meeting of the second board of directors, the "Proposal on the Adjustment and Appointment of Senior Managers" was deliberated and approved. The company is undergoing management reform, in order to adjust the management structure, combined with the company's strategic development needs, in accordance with the "Company Law", "Articles of Association" and other relevant provisions, proposed by the general manager of the company, the position of some senior management personnel is adjusted, and at the same time, according to the company's operation and management needs, new senior management personnel are hired, the details are as follows:

1. Adjustment of the company's senior management

(1) Ms. Liu Aihua

In view of the fact that Ms. Liu Aihua has exceeded the statutory retirement age, she signed a re-employment contract with the company at the time of retirement, and the re-employment contract will expire in the near future and will not be renewed after expiration. Ms. Liu Aihua will no longer hold the position of deputy general manager and will no longer hold any position in the company in the future.

(2) Ms. Xu Guixin and Mr. Luan Yizheng

In order to adjust the management structure and streamline the management level, the company has decided to reduce the number of non-statutory deputy general manager positions. Ms. Xu Guixin and Mr. Luan Yizheng no longer hold the position of deputy general manager and no longer belong to the senior management sequence, but they still work in the company as vice president of business.

As of the disclosure date of this announcement, Ms. Liu Aihua held 70,800 shares of the Company, Ms. Xu Guixin held 44,160 shares of the Company, and Mr. Luan Yizheng held 55,200 shares of the Company. After this adjustment, Ms. Liu Aihua, Ms. Xu Guixin and Mr. Luan Yizheng will continue to comply with the Rules for the Management of the Company's Shares Held by Directors, Supervisors and Senior Managers of Listed Companies and Their Changes (Revised in 2024), the Self-Regulatory Guidelines for Listed Companies on the Shanghai Stock Exchange No. 15 - Reduction of Shareholdings by Shareholders, Directors, Supervisors and Senior Managers, and the Management System for the Shares of the Company Held by Directors, Supervisors, Senior Managers and Core Technical Personnel and Their Changes. The provisions on the management of shares in the system.

Second, the appointment of the company's senior management

According to the needs of the company's operation and management, Mr. Wang Hui and Mr. Xiang Maogong were appointed as deputy general managers, and the company's nomination committee has deliberated and passed the "Proposal on Reviewing the Qualifications of Senior Management Candidates", and reviewed the qualifications of Mr. Wang Hui and Mr. Xiang Maogong.

Mr. Wang Hui is currently the Chief Financial Officer of the Company, in charge of financial management;

Mr. Xiang Maogong is currently the executive director and core technical personnel of the company's global supply chain platform, in charge of the global supply chain platform.

The term of office of the above-mentioned senior management personnel shall be from the date of deliberation and approval of the board of directors to the date of expiration of the term of the second board of directors.

As of the disclosure date of this announcement, Mr. Wang Hui and Mr. Xiang Maogong do not hold shares of the company, and have no relationship with the company's directors, supervisors, other senior managers, actual controllers and shareholders holding more than 5% of the shares, nor have they been punished by the China Securities Regulatory Commission and other relevant departments and disciplined by the stock exchange.

The announcement is hereby made.

Board of Directors of Bloomage Biotechnology Co., Ltd

March 20, 2025

Attached CV:

(1) Biography of Mr. Wang Hui

Wang Hui, male, born in September 1983, Chinese nationality, no right of permanent residence abroad, graduated from Tsinghua University

He holds a master's degree from the Department of Industrial Engineering and is a non-practicing member of the Chinese Certified Public Accountant. From 2007 to 2018, he successively served as auditor, manager and senior manager of Ernst & Young Huaming Certified Public Accountants (Special General Partnership); From 2018 to 2019, he served as the deputy general manager of the risk control department of Zhonghai Shengrong (Beijing) Capital Management Co., Ltd.; 2019-2023 Good Neighbor

Director of Finance Department of Enterprise Management Services (Beijing) Co., Ltd.; From April 2023 to September 2023, he served as CASC

Chief Financial Officer of Litton Aviation Technology Co., Ltd. He joined Bloomage Biotechnology Co., Ltd. in September 2023 and is currently the company's chief financial officer.

(2) Curriculum vitae of Mr. Xiang Maogong

Mr. Xiang Maogong, male, born in February 1984, Chinese nationality, no right of permanent residence abroad, graduated

Shandong University, majoring in microbiology and biochemical pharmacy, holds a master's degree. From 2009 to 2014, he worked in Lunan Pharmaceutical Group; From 2014 to 2015, he worked in Haida Boyuan Marine Biotechnology Co., Ltd.; From 2015 to 2021, he worked at Shandong Zhongshan Biotechnology Co., Ltd. He joined the company in March 2021 and is currently the executive director of the company's global supply chain platform and core technical personnel.